Blog Exposure - FDA Granted New 510(k) Clearance to Sonoma Pharma’s Antimicrobial Post-Therapy Gel
LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Sonoma Pharma, Inc. (NASDAQ: SNOA). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SNOA as the Company's latest news hit the wire. On April 05, 2018, the Petaluma-based pharmaceutical Company announced that the US Food and Drug Administration (FDA) has granted a new 510(k) clearance to the Company's antimicrobial post-therapy gel. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Sonoma Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=SNOA
Uses of Antimicrobial Post-Therapy Gel
The gel is intended for the management of post-non-ablative laser therapy procedures and post-microdermabrasion therapy as well for use following superficial chemical peels. It can also be used to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns. This antimicrobial post-treatment gel is a promising new tool for all dermatologists and aesthetic clinicians who are looking to better manage medical procedures, post-procedure itch and pain associated with procedures including laser skin resurfacing, while promoting enhanced healing and protection against secondary infections.
News report suggest that post announcement of the news, shares of the Company surged in premarket trade.
FDA Approval Further Fortifies Sonoma's Portfolio of Innovative Antimicrobial Dermatology Products
Jim Schutz, Chief Executive Officer of Sonoma, stated that this approval is one in a series that further fortifies Sonoma's portfolio of innovative antimicrobial dermatology products.
Jim added that with continuing efforts working with the FDA to provide best-in-class products as alternatives to topical steroids and topical antibiotics, dermatologists should have increased confidence in the Company's growing product portfolio without concern for the troubling side effects found in dated treatments.
FDA Approved Expanded Indication for Alevicyn™ to Add Antimicrobial Language
In November 2017, the FDA approved an expanded claim for Sonoma's signature dermatology product, Alevicyn™ Dermal Spray, to include antimicrobial language and antimicrobial data against clinically relevant microorganisms. This important FDA milestone further validated Alevicyn's antimicrobial activity against clinically relevant microorganisms and provided additional on-label evidence of patient benefits. In December 2017, the FDA approved an expanded antimicrobial claim for Alevicyn™ SG Antipruritic Spray Gel, reflecting the product's widening clinical utility.
About Laser Skin Resurfacing
Laser skin resurfacing, also known as a laser peel, laser vaporization, and lasabrasion, can reduce facial wrinkles, scars, and blemishes. Newer laser technologies provide surgeons with a new level of control in laser surfacing, permitting extreme precision, especially in delicate areas. The laser beam used in laser resurfacing removes outer layer of skin, called the epidermis. It simultaneously heats the underlying skin, called the dermis. This action works to stimulate growth of new collagen fibers. As the treated area heals, the newly formed skin is smoother and firmer. Common side effects include redness of the skin, swelling of the treated area, itch, pain and moderate irritation similar to the feeling produced by a mild sunburn.
About Sonoma Pharmaceuticals, Inc.
Founded in 1999 and headquartered in Petaluma, California, Sonoma Pharma is a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin conditions.
Stock Performance Snapshot
April 06, 2018 - At Friday's closing bell, Sonoma Pharma's stock fell 1.44%, ending the trading session at $4.10.
Volume traded for the day: 428.76 thousand shares, which was above the 3-month average volume of 128.19 thousand shares.
Stock performance in the last month – up 1.49%
After last Friday's close, Sonoma Pharma's market cap was at $26.20 million.
The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Other industry.
--
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
